The Role of Advanced Molecular Diagnostics in Informing Targeted Therapies for AML
Fast genetic testing now identifies treatable mutations in leukemia, fundamentally changing how doctors select the best treatment.
This review from MD Anderson's Leukemia and Hematopathology departments comprehensively covers the evolution of molecular diagnostics in AML, from conventional cytogenetics to NGS-based platforms that enable rapid identification of targetable alterations (FLT3, IDH1/2, NPM1, TP53). The authors highlight how whole-exome and whole-genome sequencing may converge toward a single diagnostic platform, and how ultrasensitive MRD assays are redefining post-remission treatment strategies.
What the study was
- Study design
- Narrative review
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Hum Pathol
Why it surfaced
Authoritative review from MD Anderson on AML molecular diagnostics and targeted therapy integration; high-relevance for clinical teams managing AML but review design limits score.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.